急性肺栓塞是一种起病急、进展快,甚至可能危及生命的肺部急症,但很多人对它知之甚少。 日前,山东第一医科大学第一附属医院(山东省千佛山医院)呼吸与危重症医学科副主任、三病区主任王光 海做客《壹点问医》,从发病原因、症状识别、规范治疗等方面,为大家详细解读了肺栓塞这种疾病。 记者 秦聪聪 济南报道 急性肺栓塞发病率攀升 高危人群需注意 王光海介绍,从临床数据来看,急性肺栓塞发病率正呈逐年上升趋势。在全球范围内,肺血栓栓塞症年发病 率为11.7/10万～131.9/10万,而我国住院患者的发病率从2007年的1.2/10万,一路上升至2021年的14.2/10万, 绝对患病人数已超过20万。这一数据的变化,既反映出疾病诊断水平的提升,也显示肺栓塞的防控已成为 公共卫生领域的重要课题。 此外,住院和手术患者、恶性肿瘤患者、心脑血管疾病及慢阻肺患者、肾病综合征患者、肥胖人群、吸 烟者,以及长途飞行久坐不动的人,都是肺栓塞的高发人群。 症状缺乏特异性 遇到警示信号别忽视 "急性肺栓塞的一大诊疗难点,在于其临床表现缺乏特异性,极易被漏诊、误诊。患者的症状轻重不一,从 毫无症状到突发心源性休克、猝死,都有可能出现。"王光海说 ...

Core Insights - The introduction of the innovative biopharmaceutical Puyouke by Tianshili represents a significant breakthrough in thrombolytic therapy for acute ischemic stroke, particularly for elderly patients who face high bleeding risks during treatment [1][2] - Recent studies published in top medical journals indicate that patients treated with Puyouke experience lower rates of hemorrhagic complications compared to control groups, highlighting its unique advantages in stroke treatment [2] - The "Lung·New Life" stroke prevention project, supported by Tianshili, aims to enhance the quality and quantity of ischemic stroke treatments in line with national health strategies, focusing on training healthcare professionals and improving public awareness [3][4] Company Developments - Tianshili's Puyouke is positioned to balance effective thrombolysis with reduced bleeding risks, enhancing its market potential and expanding the company's product line in the neurology sector [2][4] - The company is actively involved in community outreach and education initiatives to improve stroke prevention and treatment awareness, particularly in underserved areas [6][5] - Tianshili's commitment to innovation and social responsibility is evident in its support for the "Lung·New Life" project, which aims to provide comprehensive stroke care and improve healthcare access [5][7] Industry Trends - The evolution of thrombolytic therapies has shifted towards safer and more effective treatments, with Puyouke exemplifying this trend through its unique molecular structure and mechanism of action [4] - The national health strategy emphasizes the need for increased access to intravenous thrombolysis treatments in medical institutions, aligning with Tianshili's initiatives [3] - The dual focus on clinical needs and technological innovation in the pharmaceutical industry is highlighted by Tianshili's approach, which serves as a model for sustainable development in China's healthcare sector [7]

对于急性脑梗患者而言，时间就是生命。只有在有效的时间窗内进行溶栓治疗，才能真正避免脑细胞死亡和后遗症。 脑卒中，也就是常见的"中风"，已成为我国成年人致死、致残的首位病因。 "受年龄增长等各种因素影响，人的血管内可能出现斑块，一旦发生斑块破裂或者脱落，将出现中风，要通过神经介入和溶栓等再灌注治疗，尽快把堵住的 血管通开，不然每延迟一分钟，患者大脑中就有190万个神经细胞死亡。"谈及脑卒中这一当下成年人的"头号杀手"，一位三甲医院的医生极为感慨道，大脑 一旦损伤则是不可逆的，所以越早识别中风，抢救的可能性越大，愈后恢复的效果也越好。 突破时间窗，国产创新药展现治疗新希望 中国卒中学会发布的《中国卒中报告2020》统计，我国每年新发脑卒中约340万例，其中缺血性脑卒中（脑梗）占比超过70%，且发病率仍以每年4%-6%的 速度增长。 在此前宣武医院宋海庆教授团队公布的一项关于普佑克的Ⅱa期临床试验中，首次证明了普佑克静脉溶栓治疗对发病后4.5-6h的AIS患者安全有效，患者90d 功能独立率超过60%，且不增加死亡和症状性脑出血（sICH）的风险。 无论是急诊室里的争分夺秒，还是药企研发中的技术攻坚，一场围绕时间、 ...